Two More Corrections for Criticized Researchers

A university investigation has so far found no wrongdoing by the principal investigator.

Sep 22, 2016
Kerry Grens

WIKIPEDIA, KILBADA research group led by Yinsheng Wan at Providence College published corrections to two Journal of Cellular Physiology papers in recent months. Already, the team has one retraction and has corrected at least two other papers. PubPeer commenters have raised concerns about two dozen papers published by one of Wan’s coauthors, Cong Cao, who is now based at the Soochow University Institute of Neuroscience in China.

“We have been looking into the matter,” Steven Maurano, the associate vice president for public affairs, community, and government relations at Providence College, told The Scientist in an email. “At this point, we have not found any improprieties on the part of Dr. Wan or any evidence that he acted inappropriately.”

The errata, which will appear in the January issue of the Journal of Cellular Physiology, concern two 2007 papers on UV damage to human cells. In both cases, there were errors with figure panels; the researchers posted updated images in the correction notices. It appears that some of the same panels that PubPeer commenters alleged were duplicated from other figures were replaced with new ones in the updated figures.

The corrections do not mention image manipulation or duplication. However, other papers by Cao, Wan, and colleagues are known to have contained republished figures. For instance, the retraction notice for a 2008 paper in the Journal of Biological Chemistry noted that “the authors included data in Fig. 2 (AG, and H) that had been used in a previous publication.” A correction to a 2011 Science Signaling paper noted the “inadvertent use” of figures that were first published by the authors in Cancer Letters in 2008. 

Cao has also posted a correction to a 2014 BMC Cancer paper that did not include Wan as a coauthor. This erratum notes that a figure contained an error. (The authors also posted a new panel.)

In 2015, Retraction Watch reported that a former colleague of Cao, Andrew Mallon, accused Cao of misconduct. The accusation was part of a lawsuit, in which Mallon was suing their former advisor, Brown University’s John Marshall. “The lawsuit doesn’t go into many details,” according to Retraction Watch, “but does say Mallon ‘detected fabrication and falsification of data’ by Cao, and ‘Dr. Marshall excluded Dr. Mallon from submission of the PLOS Biology paper so he would not insist on proper standards of integrity of the data.’”

Cao and Wan did not immediately respond to The Scientist’s requests for comment.

A 2015 Journal of Investigative Dermatology paper coauthored by Cao is the subject of another PubPeer thread. The journal’s editor in chief, Barbara Gilchrest, responded that the figure in question was fine. “We find the authors’ interpretation of their result is accurate,” she wrote on PubPeer.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb


Sponsored Product Updates

pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!